Kimbell Royalty Partners 株価情報 (NYSE: KRP)

Kimbell Royalty Partners (NYSE:KRP) 株価情報

Kimbell Royalty Partners

Kimbell Royalty Partners LP owns and acquires mineral and royalty interests in oil and natural gas properties throughout the United States. The company's basins and producing regions include areas of interest in the Permian Basin, Mid-Continent, Terryville/Cotton Valley/Haynesville, Appalachian Basin, Eagle Ford, Bakken/Williston Basin, and DJ Basin/Rockies/Niobrara. Its revenues are derived from royalty payments received from operators based on the sale of oil, natural gas, and NGL production, as well as the sale of NGLs that are extracted from natural gas during processing.

Kimbell Royalty Partners Common Units Representing Limited Partner Interests

Kimbell Royalty Partners LP

Senseonics Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SENS#AMEX">SENS</a>) reported quarterly losses of $(0.03) per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $8.30 million which beat the analyst consensus estimate of $7.86 million by 5.60 percent. This is a 3.75 percent increase over sales of $8.00 million the same period last year.

Earnings

Earnings Beats

News

SENS

Senseonics Holdings Q4 2024 GAAP EPS $(0.03), Inline, Sales $8.30M Beat $7.86M Estimate

Guidance

GENC

Gencor Sees Prelim. 2024 Revenue $113M, Up From $105.1M YoY

Tenaya Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNYA#NASDAQ">TNYA</a>), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it intends to offer and sell units consisting of common stock and Series A warrants and Series B warrants, each to purchase shares of common stock. Tenaya may also sell to certain investors, in lieu of units, pre-funded units consisting of pre-funded warrants to purchase shares of common stock at a purchase price of $0.001 per share, Series A warrants and Series B warrants. The pre-funded warrants will be immediately exercisable and will not expire. All of the securities in this offering will be sold by Tenaya. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Biotech

Offerings

General

TNYA

Tenaya Therapeutics Announced Intention To Offer Common Stock, Series A & B Warrants

Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer;&nbsp;Roy Galvin named Executive Vice President, Chief Commercial Officer
BOSTON, March 3, 2025 /PRNewswire/ -- Haemonetics Corporation&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAE#NYSE">HAE</a>), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, Chief Operating Officer on April 7, 2025, and Roy Galvin has been appointed as the company's Executive Vice President, Chief Commercial Officer effective immediately.
As Chief Operating Officer, Chan will direct Haemonetics' research and development as well as regulatory affairs, driving innovation and operational excellence to support the company's growth.&nbsp;He will also oversee Haemonetics' global manufacturing and supply chain operations. He will report to&nbsp;Chris Simon, Haemonetics' President and Chief Executive Officer.

Management

Haemonetics Announces Executive Leadership Updates; Frank Chan Joins Haemonetics As Executive Vice President, Chief Operating Officer, Effective April 7, 2025

Keith Petri will continue to lead Lockr as its CEO.

Viant Technology Acquires Lockr For Undisclosed Terms; Acquisition Expected To Advance Addressability In Open Internet

GigaCloud Technology Appoints Erica Wei As CFO

JAMF

Jamf To Acquire Identity Automation For Approximately $215M In Cash Consideration

Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) reported quarterly losses of $(0.82) per share which beat the analyst consensus estimate of $(0.98) by 16.33 percent. This is a 18.84 percent decrease over losses of $(0.69) per share from the same period last year.

PLRX

Pliant Therapeutics Q4 2024 GAAP EPS $(0.82) Beats $(0.98) Estimate

GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) sees Q1 sales of $250.000 million-$265.000 million vs $281.40 million analyst estimate.

GigaCloud Tech Sees Q1 Sales $250.000M-$265.000M vs $281.40M Est

<a href="https://www.globenewswire.com/Tracker?data=twRU2nAwbsJZZFcl3ToARNEQtIiSBopgROyN3Y13UOGSYQM4uvG16958_yUdrx0gbAemXfD9QckQNgG35W3sqg==">ACM Research, Inc.</a> ("ACM") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACMR#NASDAQ">ACMR</a>), a leading supplier of wafer processing solutions for semiconductor and advanced packaging applications, today announced its Single-Wafer High-Temperature Sulfuric Peroxide Mixture (SPM) tool has been qualified by a key logic device manufacturer in mainland China. To date, ACM has delivered its SPM tools to thirteen customers. The system features ACM's proprietary nozzle design, which prevents acid mist splatter during the SPM process, improving particle performance, reducing chamber preventive maintenance cleaning frequency, and enhancing system uptime. It supports wet etching and wafer cleaning for both front- and back-end processes at 28-nanometer (nm) and below technology nodes.

Global

ACMR

ACM Research Announces Qualification Of High-Temperature SPM Tool For Customer In China

WIIM

NATL

NCR Atleos shares are trading lower. The company reported Q4 financial results.

Ekso Bionics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EKSO#NASDAQ">EKSO</a>) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.07) by 100 percent. This is a 36.36 percent increase over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $5.09 million which beat the analyst consensus estimate of $5.05 million by 0.74 percent. This is a 5.01 percent increase over sales of $4.85 million the same period last year.

Earnings Misses

EKSO

Ekso Bionics Holdings Q4 EPS $(0.14) Misses $(0.07) Estimate, Sales $5.09M Beat $5.05M Estimate

GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) reported quarterly earnings of $0.75 per share which missed the analyst consensus estimate of $0.81 by 7.41 percent. This is a 29.91 percent decrease over earnings of $1.07 per share from the same period last year. The company reported quarterly sales of $295.782 million which beat the analyst consensus estimate of $288.333 million by 2.58 percent. This is a 20.86 percent increase over sales of $244.737 million the same period last year.

GigaCloud Tech Q4 2024 Adj. EPS $0.75 Misses $0.81 Estimate, Sales $295.782M Beat $288.333M Estimate

ATEC

Alphatec shares are trading lower after the company announced a proposed $300 million convertible senior note offering.

SRPT

Sarepta Therapeutics Files For Mixed Shelf; Size Not Disclosed

The contracts were awarded in the first quarter of 2025 and fourth quarter of 2024. Both have a four-year period of performance.

Contracts

ICFI

ICF Reveals Two Significant Wins With Combined Ceiling Value Of Over $210M, One With European Commission And Other With UK Government

AAR CORP. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIR#NYSE">AIR</a>), a leading provider of aviation services to commercial and government operators, MROs, and OEMs, has added distribution support of select Unison parts under its Supplier Capabilities Contract with Defense Logistics Agency (DLA) Aviation.
"In 2022, AAR was the first non-OEM to be awarded a 20-year base Supplier Capabilities Contract with the DLA."
This multiple year agreement leverages&nbsp;AAR's exclusive distribution capabilities for sole source spare parts manufactured by Unison in support of various military aircraft platforms. AAR will provide comprehensive and integrated supply chain management support and perform associated functions to maximize the availability of parts to the DLA. This relationship reduces supply volatility through improved material availability.

AAR Has Added Distribution Support Of Select Unison Parts Under Its Supplier Capabilities Contract With Defense Logistics Agency Aviation

10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences. Through a consent agreement entered on February 25, 2025, in the United States District Court for the District of Delaware, Parse agreed - a week before trial was to start - to a worldwide permanent injunction that prevents it from making, using, selling or offering for sale its planned ATAC and ATAC-Multiome Single Cell products. As part of this consent agreement, Parse admitted that 10x's ATAC-seq patents are valid, enforceable and infringed by Parse's use of ATAC-seq methods and compositions.

10x Genomics Announces Consent Agreement: Parse Biosciences Agrees to Worldwide Permanent Injunction On ATAC Products, Admits Infringement Of 10x ATAC-Seq Patents

DAVE

Dave shares are trading higher after the company reported better-than-expected Q4 financial results.

Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.19) by 21.05 percent. This is a 43.75 percent decrease over losses of $(0.16) per share from the same period last year. The company reported quarterly sales of $1.19 million which missed the analyst consensus estimate of $1.23 million by 2.83 percent. This is a 198.00 percent increase over sales of $400.00 thousand the same period last year.

Quantum-Si Q4 EPS $(0.23) Misses $(0.19) Estimate, Sales $1.19M Miss $1.23M Estimate

Commodities

Press Releases

Kimbell Royalty Partners Announces Date for Third Quarter 2024 Earnings Release and Conference Call

Kimbell Royalty Partners Announces Third Quarter 2024 Results

Kimbell Royalty Partners Announces Participation at Upcoming Investor Conferences

Kimbell Royalty Partners Announces Date for Fourth Quarter 2024 Earnings Release and Conference Call

Kimbell Royalty Partners, LP Announces $231 Million Midland Basin Acquisition in Cash and Unit Transaction(1)

Kimbell Royalty Partners, LP Announces Public Offering of Common Units

Kimbell Royalty Partners, LP Announces Pricing of Upsized Public Offering of Common Units

Kimbell Royalty Partners Closes $230 Million Acquisition of Midland Basin Mineral and Royalty Interests in Cash Transaction

Kimbell Royalty Partners Announces Record Fourth Quarter and Full Year 2024 Results

Kimbell Royalty Partners Announces Filing of 2024 Annual Report on Form 10-K

Black Stone Minerals, L.P. Common units representing limited partner interests

Black Stone Minerals

Civitas Resources

Crescent Energy Company Class A Common Stock

Crescent Energy

Dorchester Minerals, L.P. - Common Units Representing Limited Partnership Interests

Dorchester Minerals

VAALCO Energy

Greenfire Resources

Gulfport Energy Corporation Common Shares

Gulfport Energy

GeoPark

Granite Ridge Resources, Inc. Common Stock

Granite Ridge Resources

HighPeak Energy

Kosmos Energy

Mach Natural Resources LP Common Units representing Limited Partner Interests

Mach Natural Resources

Northern Oil & Gas

Permian Basin Royalty

Riley Exploration Permian, Inc. Common Stock

Riley Exploration Permian

Sabine Royalty

SandRidge Energy

Sable Offshore

Sitio Royalties Corp. Class A Common Stock

Sitio Royalties

Talos Energy

Tamboran Resources Corporation Common stock

Tamboran Resources

TXO Partners, L.P. Common Units Representing Limited Partner Interests

TXO Partners

Vital Energy, Inc. Common Stock, par value $0.01 per share

Comments

Kimbell Royalty Partners

ニュース

パートナーシップ

ベンジンガ・グローバル